| NCT ID | NCT07234201 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | Intensive Care Unit ICU |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-12-01 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to explore if Virtual Reality (VR) helps patients in the Intensive Care Unit (ICU) move more and feel better.
Eligibility Criteria
Inclusion Criteria: * English speaking * Adults age 18 or greater * ICU stay greater or equal to 3 days * Limited mobility Exclusion Criteria: * Pregnancy * Special enteric contact isolation * Blindness * History of seizure or vertigo * Intubated and sedated * ICU delirium
Contact & Investigator
Anna Mall
PRINCIPAL INVESTIGATOR
Duke University
Frequently Asked Questions
Who can join the NCT07234201 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intensive Care Unit ICU. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07234201 currently recruiting?
Yes, NCT07234201 is actively recruiting participants. Contact the research team at anna.mall@duke.edu for enrollment information.
Where is the NCT07234201 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT07234201 clinical trial?
NCT07234201 is sponsored by Duke University. The principal investigator is Anna Mall at Duke University. The trial plans to enroll 60 participants.